# G-HOPE-001 (NCT06238843)

> A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06238843
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions: Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）; IBI343
- Enrollment: 464
- Primary outcome: progression free survival(PFS)
- Primary outcome: overall survival(OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=g-hope-001-nct06238843

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06238843", "email": "<work email>"}; the inbox owner confirms by the emailed link.